Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Increase in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 500,465 shares, an increase of 24.7% from the February 26th total of 401,483 shares. Currently, 19.8% of the company’s shares are short sold. Based on an average trading volume of 181,083 shares, the days-to-cover ratio is currently 2.8 days.

Aspire Biopharma Stock Performance

Shares of Aspire Biopharma stock opened at $0.93 on Tuesday. The company has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $6.07. Aspire Biopharma has a 52-week low of $0.55 and a 52-week high of $35.01. The stock has a market capitalization of $2.49 million, a PE ratio of -0.05 and a beta of 0.89.

Aspire Biopharma (NASDAQ:ASBP) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.00 million for the quarter.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC grew its position in Aspire Biopharma by 2,252.1% during the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd grew its position in shares of Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Aspire Biopharma during the 3rd quarter valued at $28,000. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on ASBP. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.